Advances in Targeting HER3 as an Anticancer Therapy

HER3 (ErbB3) is a unique member of the human epidermal growth factor receptor (EGFR) family (ErbB family). It functions only through dimerization with other members of the ErbB family and modulates activity and sensitivity to targeted cancer therapies. This paper briefly describes the mechanism of H...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Ning, Saba, Nabil F., Chen, Zhuo Georgia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502787/
https://www.ncbi.nlm.nih.gov/pubmed/23198146
http://dx.doi.org/10.1155/2012/817304
_version_ 1782250393336545280
author Jiang, Ning
Saba, Nabil F.
Chen, Zhuo Georgia
author_facet Jiang, Ning
Saba, Nabil F.
Chen, Zhuo Georgia
author_sort Jiang, Ning
collection PubMed
description HER3 (ErbB3) is a unique member of the human epidermal growth factor receptor (EGFR) family (ErbB family). It functions only through dimerization with other members of the ErbB family and modulates activity and sensitivity to targeted cancer therapies. This paper briefly describes the mechanism of HER3 in signal transduction and its potential role in acquired resistance to EGFR- and HER2-targeted therapies. We also consider recent developments in HER3-targeting therapeutics and their combination with inhibitors of other ErbB members in clinical applications.
format Online
Article
Text
id pubmed-3502787
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-35027872012-11-29 Advances in Targeting HER3 as an Anticancer Therapy Jiang, Ning Saba, Nabil F. Chen, Zhuo Georgia Chemother Res Pract Review Article HER3 (ErbB3) is a unique member of the human epidermal growth factor receptor (EGFR) family (ErbB family). It functions only through dimerization with other members of the ErbB family and modulates activity and sensitivity to targeted cancer therapies. This paper briefly describes the mechanism of HER3 in signal transduction and its potential role in acquired resistance to EGFR- and HER2-targeted therapies. We also consider recent developments in HER3-targeting therapeutics and their combination with inhibitors of other ErbB members in clinical applications. Hindawi Publishing Corporation 2012 2012-11-07 /pmc/articles/PMC3502787/ /pubmed/23198146 http://dx.doi.org/10.1155/2012/817304 Text en Copyright © 2012 Ning Jiang et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Jiang, Ning
Saba, Nabil F.
Chen, Zhuo Georgia
Advances in Targeting HER3 as an Anticancer Therapy
title Advances in Targeting HER3 as an Anticancer Therapy
title_full Advances in Targeting HER3 as an Anticancer Therapy
title_fullStr Advances in Targeting HER3 as an Anticancer Therapy
title_full_unstemmed Advances in Targeting HER3 as an Anticancer Therapy
title_short Advances in Targeting HER3 as an Anticancer Therapy
title_sort advances in targeting her3 as an anticancer therapy
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502787/
https://www.ncbi.nlm.nih.gov/pubmed/23198146
http://dx.doi.org/10.1155/2012/817304
work_keys_str_mv AT jiangning advancesintargetingher3asananticancertherapy
AT sabanabilf advancesintargetingher3asananticancertherapy
AT chenzhuogeorgia advancesintargetingher3asananticancertherapy

Ejemplares similares